Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00585559 · ClinicalTrials.gov registry record · Phase 3
Acetaminophen in aSAH to Inhibit Lipid Peroxidation and Cerebral Vasospasm
A Phase 3 study, sponsored by Vanderbilt University Medical Center.
- Terminated
- Registry status
- Phase 3
- Development phase
- 44
- Enrollment target
NCT00585559 is a Phase 3 study that was terminated before completion, run by Vanderbilt University Medical Center. The registered enrollment target is 44 participants.
The verdict
NCT00585559, a Phase 3 study, was terminated before completion, sponsored by Vanderbilt University Medical Center.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 44 participants
- Enrollment target
Study Summary
The objective of this study is to determine whether acetaminophen (APAP), N-acetylcysteine (NAC), and APAP in combination with NAC will inhibit lipid peroxidation in aneurysmal subarachnoid hemorrhage (aSAH), utilizing F2-IsoPs as biomarkers for lipid peroxidation.
Interventions
- DRUG Placebos for acetaminophen and N-acetylcysteine
- DRUG APAP 1 gm every 6 hours and N-acetylcysteine placebo
- DRUG NAC IV infusion at 0.5 gm hourly and APAP placebo
- DRUG APAP 1 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly
- DRUG APAP 1.5 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2007-04 |
| Est. Completion | 2023-10-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00585559
The ClinicalTrials.gov registry entry for NCT00585559 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebos for acetaminophen and N-acetylcysteine is the first listed.
NCT00585559 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00585559 about?
NCT00585559 is a clinical study titled "Acetaminophen in aSAH to Inhibit Lipid Peroxidation and Cerebral Vasospasm". The objective of this study is to determine whether acetaminophen (APAP), N-acetylcysteine (NAC), and APAP in combination with NAC will inhibit lipid peroxidation in aneurysmal subarachnoid hemorrhage (aSAH), utilizing F2-IsoPs as biomarkers for lipid peroxidation.
What is the current status of trial NCT00585559?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 44 participants. The study started on 2007-04. Estimated completion is 2023-10-26.
What interventions are being tested in trial NCT00585559?
The interventions under investigation include: Placebos for acetaminophen and N-acetylcysteine (DRUG), APAP 1 gm every 6 hours and N-acetylcysteine placebo (DRUG), NAC IV infusion at 0.5 gm hourly and APAP placebo (DRUG), APAP 1 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly (DRUG), APAP 1.5 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly (DRUG).
Who is sponsoring clinical trial NCT00585559?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.